Suppr超能文献

激活的 ALK 与 MYCN 在神经母细胞瘤发病机制中协同作用。

Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

机构信息

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Cancer Cell. 2012 Mar 20;21(3):362-73. doi: 10.1016/j.ccr.2012.02.010.

Abstract

Amplification of the MYCN oncogene in childhood neuroblastoma is often accompanied by mutational activation of ALK (anaplastic lymphoma kinase), suggesting their pathogenic cooperation. We generated a transgenic zebrafish model of neuroblastoma in which MYCN-induced tumors arise from a subpopulation of neuroblasts that migrate into the adrenal medulla analog following organogenesis. Coexpression of activated ALK with MYCN in this model triples the disease penetrance and markedly accelerates tumor onset. MYCN overexpression induces adrenal sympathetic neuroblast hyperplasia, blocks chromaffin cell differentiation, and ultimately triggers a developmentally-timed apoptotic response in the hyperplastic sympathoadrenal cells. Coexpression of activated ALK with MYCN provides prosurvival signals that block this apoptotic response and allow continued expansion and oncogenic transformation of hyperplastic neuroblasts, thus promoting progression to neuroblastoma.

摘要

在儿童神经母细胞瘤中,MYCN 癌基因的扩增通常伴随着 ALK(间变性淋巴瘤激酶)的突变激活,提示它们具有致病协同作用。我们构建了一种神经母细胞瘤的转基因斑马鱼模型,其中 MYCN 诱导的肿瘤起源于一群神经母细胞,它们在器官发生后迁移到肾上腺髓质类似物中。在该模型中,与 MYCN 共表达激活的 ALK 使疾病的穿透率增加两倍,并显著加速肿瘤的发生。MYCN 过表达诱导肾上腺交感神经母细胞增生,阻止嗜铬细胞分化,最终在增生的交感肾上腺细胞中引发发育定时的凋亡反应。与 MYCN 共表达激活的 ALK 提供了生存信号,阻止了这种凋亡反应,并允许增生的神经母细胞继续扩张和致癌转化,从而促进神经母细胞瘤的进展。

相似文献

1
Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
Cancer Cell. 2012 Mar 20;21(3):362-73. doi: 10.1016/j.ccr.2012.02.010.
2
Neuroblastoma and Its Zebrafish Model.
Adv Exp Med Biol. 2016;916:451-78. doi: 10.1007/978-3-319-30654-4_20.
3
Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
J Neurosci. 2016 Oct 5;36(40):10425-10439. doi: 10.1523/JNEUROSCI.0183-16.2016.
4
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Oncogene. 2012 Dec 13;31(50):5193-200. doi: 10.1038/onc.2012.12. Epub 2012 Jan 30.
6
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Cancer Cell. 2012 Jul 10;22(1):117-30. doi: 10.1016/j.ccr.2012.06.001.
8
MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
Oncogene. 2013 Feb 21;32(8):1059-65. doi: 10.1038/onc.2012.106. Epub 2012 Apr 9.
9
ALK pERKs up MYCN in neuroblastoma.
Sci Signal. 2014 Oct 28;7(349):pe27. doi: 10.1126/scisignal.2005940.

引用本文的文献

3
Peripheral neuroblastic tumors behaving badly: an update on high-risk morphologic and molecular groupings.
Virchows Arch. 2025 May;486(5):895-903. doi: 10.1007/s00428-025-04083-9. Epub 2025 Mar 29.
4
ALK in cancer: from function to therapeutic targeting.
Nat Rev Cancer. 2025 May;25(5):359-378. doi: 10.1038/s41568-025-00797-9. Epub 2025 Mar 7.
6
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma.
Neoplasia. 2025 Feb;60:100964. doi: 10.1016/j.neo.2024.100964. Epub 2024 Jan 6.
7
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
Genes Dis. 2023 Oct 27;12(2):101156. doi: 10.1016/j.gendis.2023.101156. eCollection 2025 Mar.
10
Expansion of a neural crest gene signature following ectopic MYCN expression in sympathoadrenal lineage cells in vivo.
PLoS One. 2024 Sep 18;19(9):e0310727. doi: 10.1371/journal.pone.0310727. eCollection 2024.

本文引用的文献

2
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Cancer Res. 2010 Dec 15;70(24):10038-43. doi: 10.1158/0008-5472.CAN-10-2956. Epub 2010 Oct 28.
3
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
N Engl J Med. 2010 Oct 28;363(18):1727-33. doi: 10.1056/NEJMoa1007056.
4
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
5
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18.
6
Recent advances in neuroblastoma.
N Engl J Med. 2010 Jun 10;362(23):2202-11. doi: 10.1056/NEJMra0804577.
7
Molecular pathogenesis of peripheral neuroblastic tumors.
Oncogene. 2010 Mar 18;29(11):1566-79. doi: 10.1038/onc.2009.518. Epub 2010 Jan 25.
8
MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.
Am J Pathol. 2009 Aug;175(2):856-66. doi: 10.2353/ajpath.2009.090019. Epub 2009 Jul 16.
9
Anaplastic lymphoma kinase: signalling in development and disease.
Biochem J. 2009 May 27;420(3):345-61. doi: 10.1042/BJ20090387.
10
Activating mutations in ALK provide a therapeutic target in neuroblastoma.
Nature. 2008 Oct 16;455(7215):975-8. doi: 10.1038/nature07397.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验